Cargando…
Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply
Autores principales: | Kosiborod, Mikhail N, Esterline, Russell, Oscarsson, Jan, Gasparyan, Samvel B, Furtado, Remo H M, Verma, Subodh, Berwanger, Otavio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673873/ https://www.ncbi.nlm.nih.gov/pubmed/34921753 http://dx.doi.org/10.1016/S2213-8587(21)00326-0 |
Ejemplares similares
-
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
por: Kosiborod, Mikhail, et al.
Publicado: (2021) -
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
por: Gasparyan, Samvel B., et al.
Publicado: (2022) -
Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 – Authors' reply
por: Lopes, Renato D, et al.
Publicado: (2021) -
Dapagliflozin in patients with COVID-19: mind the kidneys
por: Reis, Thiago, et al.
Publicado: (2022) -
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
por: Kosiborod, Mikhail N, et al.
Publicado: (2021)